Weekly Research Analysts’ Ratings Changes for Fate Therapeutics (FATE)

Several analysts have recently updated their ratings and price targets for Fate Therapeutics (NASDAQ: FATE):

• 11/7/2026 – Fate Therapeutics was downgraded by Wall Street Zen from “hold” to “sell”.
• 11/6/2026 – Fate Therapeutics had its price target lowered by Wells Fargo & Company from $3.50 to $3.00. They now have an “equal weight” rating on the stock.
• 11/4/2026 – Fate Therapeutics had its “sell (d-)” rating reaffirmed by Weiss Ratings.
• 10/27/2026 – Fate Therapeutics had its “outperform” rating reaffirmed by Wedbush. They now have a $7.00 price target on the stock.

Fate Therapeutics Stock Performance

Shares of FATE traded up $0.10 during midday trading on Monday, hitting $1.94. 2,213,360 shares of the company traded hands, compared to its average volume of 2,313,896. The stock has a market cap of $235.77 million, a price-to-earnings ratio of -1.88 and a beta of 2.65. The firm has a 50 day moving average of $2.24 and a 200-day moving average of $1.97. Fate Therapeutics, Inc. has a 52 week low of $0.95 and a 52 week high of $3.23.

Fate Therapeutics (NASDAQ:FATE) last announced its quarterly earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.25) EPS for the quarter, beating analysts’ consensus estimates of ($0.27) by $0.02. The company had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.14 million. Fate Therapeutics had a negative return on equity of 73.92% and a negative net margin of 1,941.09%. Sell-side analysts predict that Fate Therapeutics, Inc. will post -1.03 earnings per share for the current fiscal year.

Fate Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing cellular immunotherapies for cancer and autoimmune diseases. The company uses induced pluripotent stem cell (iPSC) technology to create standardized, potentially off-the-shelf immune cell products, including natural killer (NK) cells and T cells.

Its research and development activities include iPSC-derived cell therapies engineered to recognize and attack cancer cells. Fate’s pipeline has included candidates such as FT819, an iPSC-derived, CD19-targeted CAR T-cell therapy, along with other investigational NK-cell and T-cell programs.